IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both

R. Ruckert, U. Herz, Ralf Paus, D. Ungureanu, T. Pohl, H. Renz, S. Bulfone-Paus

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We have explored how IL-15 influences Th1 or Th2 type immune response in vivo. Intraperitoneal application of an IL-15-IgG2b fusion protein (FP) to mice did neither significantly affect the footpad swelling nor the production of hemagglutinizing antibodies in a delayed type hypersensitivity reaction to sheep red blood cells. In contrast, in an established murine Th2 model of sensitization to ovalbumin (OVA), IL-15-IgG2b FP plus OVA sensitization resulted in massively accelerated and enhanced allergen-specific IgE and IgG1 antibody production. In vitro, stimulation of spleen cells from OVA-sensitized mice with OVA + IL-15 or OVA + IL-15-IgG2b resulted in a significantly enhanced IgE production. IL-4 secretion was significantly induced by IL-15 but not by IL-15-IgG2b. An IL-2-IgG2b FP with the same Fc tail as the IL-15-IgG2b FP was used as control in both models. In striking contrast to the IL-15-IgG2b FP, IL-2-IgG2b significantly inhibited the Th2 type antibody production in vivo. The current study suggests that IL-15-IgG2b may be employed as a potent accelerator and enhancer of Th2 type immune responses in vivo, while IL-2-IgG2b can suppress the latter.

Original languageEnglish (US)
Pages (from-to)3312-3320
Number of pages9
JournalEuropean Journal of Immunology
Volume28
Issue number10
DOIs
StatePublished - Oct 26 1998
Externally publishedYes

Fingerprint

Interleukin-15
Interleukin-2
Ovalbumin
Proteins
Antibody Formation
Immunoglobulin E
Delayed Hypersensitivity
Interleukin-4
Allergens
Tail
Sheep
Spleen
Immunoglobulin G
Erythrocytes

Keywords

  • Fusion protein
  • IL-15
  • IL-2
  • Th1
  • Th2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both. / Ruckert, R.; Herz, U.; Paus, Ralf; Ungureanu, D.; Pohl, T.; Renz, H.; Bulfone-Paus, S.

In: European Journal of Immunology, Vol. 28, No. 10, 26.10.1998, p. 3312-3320.

Research output: Contribution to journalArticle

Ruckert, R. ; Herz, U. ; Paus, Ralf ; Ungureanu, D. ; Pohl, T. ; Renz, H. ; Bulfone-Paus, S. / IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both. In: European Journal of Immunology. 1998 ; Vol. 28, No. 10. pp. 3312-3320.
@article{400bc4a72d4f4ab39a248bbb63a685b3,
title = "IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both",
abstract = "We have explored how IL-15 influences Th1 or Th2 type immune response in vivo. Intraperitoneal application of an IL-15-IgG2b fusion protein (FP) to mice did neither significantly affect the footpad swelling nor the production of hemagglutinizing antibodies in a delayed type hypersensitivity reaction to sheep red blood cells. In contrast, in an established murine Th2 model of sensitization to ovalbumin (OVA), IL-15-IgG2b FP plus OVA sensitization resulted in massively accelerated and enhanced allergen-specific IgE and IgG1 antibody production. In vitro, stimulation of spleen cells from OVA-sensitized mice with OVA + IL-15 or OVA + IL-15-IgG2b resulted in a significantly enhanced IgE production. IL-4 secretion was significantly induced by IL-15 but not by IL-15-IgG2b. An IL-2-IgG2b FP with the same Fc tail as the IL-15-IgG2b FP was used as control in both models. In striking contrast to the IL-15-IgG2b FP, IL-2-IgG2b significantly inhibited the Th2 type antibody production in vivo. The current study suggests that IL-15-IgG2b may be employed as a potent accelerator and enhancer of Th2 type immune responses in vivo, while IL-2-IgG2b can suppress the latter.",
keywords = "Fusion protein, IL-15, IL-2, Th1, Th2",
author = "R. Ruckert and U. Herz and Ralf Paus and D. Ungureanu and T. Pohl and H. Renz and S. Bulfone-Paus",
year = "1998",
month = "10",
day = "26",
doi = "10.1002/(SICI)1521-4141(199810)28:10<3312::AID-IMMU3312>3.0.CO;2-I",
language = "English (US)",
volume = "28",
pages = "3312--3320",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "10",

}

TY - JOUR

T1 - IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both

AU - Ruckert, R.

AU - Herz, U.

AU - Paus, Ralf

AU - Ungureanu, D.

AU - Pohl, T.

AU - Renz, H.

AU - Bulfone-Paus, S.

PY - 1998/10/26

Y1 - 1998/10/26

N2 - We have explored how IL-15 influences Th1 or Th2 type immune response in vivo. Intraperitoneal application of an IL-15-IgG2b fusion protein (FP) to mice did neither significantly affect the footpad swelling nor the production of hemagglutinizing antibodies in a delayed type hypersensitivity reaction to sheep red blood cells. In contrast, in an established murine Th2 model of sensitization to ovalbumin (OVA), IL-15-IgG2b FP plus OVA sensitization resulted in massively accelerated and enhanced allergen-specific IgE and IgG1 antibody production. In vitro, stimulation of spleen cells from OVA-sensitized mice with OVA + IL-15 or OVA + IL-15-IgG2b resulted in a significantly enhanced IgE production. IL-4 secretion was significantly induced by IL-15 but not by IL-15-IgG2b. An IL-2-IgG2b FP with the same Fc tail as the IL-15-IgG2b FP was used as control in both models. In striking contrast to the IL-15-IgG2b FP, IL-2-IgG2b significantly inhibited the Th2 type antibody production in vivo. The current study suggests that IL-15-IgG2b may be employed as a potent accelerator and enhancer of Th2 type immune responses in vivo, while IL-2-IgG2b can suppress the latter.

AB - We have explored how IL-15 influences Th1 or Th2 type immune response in vivo. Intraperitoneal application of an IL-15-IgG2b fusion protein (FP) to mice did neither significantly affect the footpad swelling nor the production of hemagglutinizing antibodies in a delayed type hypersensitivity reaction to sheep red blood cells. In contrast, in an established murine Th2 model of sensitization to ovalbumin (OVA), IL-15-IgG2b FP plus OVA sensitization resulted in massively accelerated and enhanced allergen-specific IgE and IgG1 antibody production. In vitro, stimulation of spleen cells from OVA-sensitized mice with OVA + IL-15 or OVA + IL-15-IgG2b resulted in a significantly enhanced IgE production. IL-4 secretion was significantly induced by IL-15 but not by IL-15-IgG2b. An IL-2-IgG2b FP with the same Fc tail as the IL-15-IgG2b FP was used as control in both models. In striking contrast to the IL-15-IgG2b FP, IL-2-IgG2b significantly inhibited the Th2 type antibody production in vivo. The current study suggests that IL-15-IgG2b may be employed as a potent accelerator and enhancer of Th2 type immune responses in vivo, while IL-2-IgG2b can suppress the latter.

KW - Fusion protein

KW - IL-15

KW - IL-2

KW - Th1

KW - Th2

UR - http://www.scopus.com/inward/record.url?scp=0031711479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031711479&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1521-4141(199810)28:10<3312::AID-IMMU3312>3.0.CO;2-I

DO - 10.1002/(SICI)1521-4141(199810)28:10<3312::AID-IMMU3312>3.0.CO;2-I

M3 - Article

VL - 28

SP - 3312

EP - 3320

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 10

ER -